Shield Therapeutics Readies H1 2024 Results
Company Announcements

Shield Therapeutics Readies H1 2024 Results

Shield Therapeutics (GB:STX) has released an update.

Shield Therapeutics plc, a commercial stage pharmaceutical company, is set to announce its interim results for the first half of 2024 on September 4th. The company, known for its innovative oral iron treatment Accrufer®/Feraccru®, addresses iron deficiency in patients globally. An investor presentation by the Interim CEO and CFO will be hosted online, open to all interested parties.

For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskShield Therapeutics Sees Revenue Surge and Financial Boost
TipRanks UK Auto-Generated NewsdeskShield Therapeutics’ Pediatric IDA Trial Succeeds
TipRanks UK Auto-Generated NewsdeskShield Therapeutics Sees Strong Revenue Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App